Kodiak Sciences (NASDAQ:KOD) Reaches New 52-Week High – Time to Buy?

Kodiak Sciences Inc. (NASDAQ:KOD) shares hit a new 52-week high during trading on Thursday . The company traded as high as $36.84 and last traded at $36.0160, with a volume of 3075248 shares. The stock had previously closed at $22.75.

More Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Topline Phase 3 (GLOW2) win for Zenkuda: Kodiak reported that Zenkuda (tarcocimab tedromer) met the primary endpoint in GLOW2, showing a large improvement in diabetic retinopathy severity (62.5% of treated patients achieved ≥2‑step DRSS improvement vs 3.3% for sham) with a 6‑month dosing interval — a result that materially raises the drug’s efficacy and commercial prospects. PR Newswire
• Positive Sentiment: Market reaction: The GLOW2 news triggered large intraday rallies (reports of 50–75%+ moves) as traders repriced KOD for a potential regulatory filing and eventual launch. This surge reflected investor expectations that the program can support a Biologics License Application (BLA) and a valuable ophthalmology franchise. Reuters
• Positive Sentiment: Analyst upgrades and higher price targets: Following the data, UBS raised its price target to $80 with a Buy rating and HC Wainwright reaffirmed Buy while raising its target to $58 — both moves signal increased sell‑side conviction and provide further upside narrative for investors. Benzinga (UBS) TickerReport (HC Wainwright)
• Neutral Sentiment: Regulatory path and next steps: Coverage notes and industry press indicate a likely BLA filing is now the logical next step; timing and FDA interactions remain catalysts but are not guaranteed. Positive data increase probability, but approval and commercial uptake timelines still carry execution risk. BioWorld
• Negative Sentiment: Volatility and hedging activity: There was unusually high put option activity the day of the results (large put volumes vs typical), indicating some traders were hedging or positioning for downside — a sign of elevated speculative interest and potential for sharp intraday reversals. (Options flow reported 3,472 puts vs typical ~256.)
• Negative Sentiment: Today’s pullback amid heavy volume: After the strong rally on the data, the shares have pulled back today on very heavy trading — a common post‑news profit taking and volatility washout that increases short‑term risk despite the fundamentally positive trial news.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KOD. HC Wainwright reiterated a “buy” rating and set a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a report on Friday. UBS Group increased their price objective on shares of Kodiak Sciences from $50.00 to $80.00 and gave the company a “buy” rating in a research note on Friday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kodiak Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $35.43.

Kodiak Sciences Stock Down 6.9%

The firm has a market cap of $1.96 billion, a P/E ratio of -8.98 and a beta of 2.61. The firm’s 50-day simple moving average is $25.14 and its 200 day simple moving average is $21.81.

Institutional Investors Weigh In On Kodiak Sciences

A number of hedge funds have recently modified their holdings of KOD. AQR Capital Management LLC purchased a new position in Kodiak Sciences in the first quarter valued at approximately $188,000. Dynamic Technology Lab Private Ltd purchased a new stake in Kodiak Sciences in the first quarter worth $94,000. Jane Street Group LLC raised its stake in shares of Kodiak Sciences by 441.3% in the first quarter. Jane Street Group LLC now owns 64,649 shares of the company’s stock valued at $181,000 after buying an additional 52,705 shares during the period. American Century Companies Inc. raised its stake in shares of Kodiak Sciences by 6.3% in the second quarter. American Century Companies Inc. now owns 79,745 shares of the company’s stock valued at $297,000 after buying an additional 4,703 shares during the period. Finally, Panagora Asset Management Inc. lifted its position in shares of Kodiak Sciences by 28.5% during the 2nd quarter. Panagora Asset Management Inc. now owns 131,122 shares of the company’s stock valued at $489,000 after buying an additional 29,113 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.